Edwards Lifesciences Corporation EW
Composite 56/100; the shares have moved about 26% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 25/100 — a strong mark against it.
Balance-sheet strength ranks 92/100 — a strong point in its favour. Quality ranks 62/100 — a slight point in its favour. Momentum ranks 53/100 — a slight point in its favour.
Valuation ranks 25/100 — a strong mark against it. Growth ranks 45/100 — a slight mark against it.
What the company does Edwards Lifesciences designs and sells transcatheter and surgical heart valves and repair systems, including the SAPIEN, PASCAL, and INSPIRIS brands, serving cardiovascular disease markets globally.
Key financials Revenue grew 13.6% while EPS fell 25.4%, reflecting margin pressure despite top-line strength. Gross margin is 77.8%, operating margin 29.8%, and net margin 15.4%. ROE is 9.2% and ROA is 8.4%.
Stock health Momentum is strong: +21.37% over 3 months, +21.95% over 6 months, and +19.54% over 12 months. RSI(14) is 67.70, indicating elevated but not extreme overbought conditions.
Price vs fair value The stock trades at a **discount of 7.80%** versus the analyst mean target of 100.96. - Forward P/E of 29.85 is rich vs 5-year average (Sideravia Valuation 21.4/100). - PEG of 0.38 signals undervaluation relative to growth (Sideravia). - Strength score of 93.0 reflects strong competitive position and product pipeline.
Looking forward Analysts expect continued revenue growth driven by structural heart market expansion, but margin normalization may weigh on near-term EPS. Valuation remains sensitive to procedural volumes and reimbursement updates.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.